Skip to main content
Premium Trial:

Request an Annual Quote

Meridian Bioscience's Bioline Unit to Directly Market Products in Australia

Premium

Meridian Bioscience said today that it will now directly distribute its diagnostic products in Australia through its subsidiary Bioline Australia.

Cincinnati, Ohio-based Meridian said that it is transitioning sales of its diagnostic products from its current distributor to a direct sales force through Bioline, which is headquartered in London but has branches in Sydney, Boston, and Berlin.

Meridian's portfolio of infectious disease diagnostic products includes both traditional immunoassays and the company's newer molecular platform, Illumigene, which uses loop-mediated isothermal amplification technology, and will be the primary product offering through Bioline. Currently, Meridian offers only an Illumigene test for C. difficile, but is also developing a test for Group B Streptococcus.

Meridian acquired Bioline in July 2010 for $23.3 million in a bid to expand both its PCR and molecular diagnostics plays (PCR Insider 7/22/10).

"Combining our Australian business through Bioline/Meridian was a strategic decision toward strengthening our global distribution," Richard Eberly, chief commercial officer of Meridian, said in a statement.

Meridian had previously inked an exclusive distribution agreement in Australia in 2009 with Immuno Pty.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.